# Aftobetin-HCl and Fluorescence Detection Measured by Sapphire II to Determine the Number and Timing of Administrations

> **NCT02928211** · PHASE1 · UNKNOWN · sponsor: **Cognoptix, Inc.** · enrollment: 105 (estimated)

## Conditions studied

- Mild Cognitive Impairment
- Alzheimer's Disease

## Interventions

- **DEVICE:** Sapphire II
- **DRUG:** Aftobetin-HCl
- **RADIATION:** Positron Emission Tomography

## Key facts

- **NCT ID:** NCT02928211
- **Lead sponsor:** Cognoptix, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2016-07
- **Primary completion:** 2018-12
- **Final completion:** 2019-01
- **Target enrollment:** 105 (ESTIMATED)
- **Last updated:** 2018-08-22


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02928211

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02928211, "Aftobetin-HCl and Fluorescence Detection Measured by Sapphire II to Determine the Number and Timing of Administrations". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT02928211. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*